Telix Pharmaceuticals Ltd (ASX: TLX) shares are charging higher today.
Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $15.10. In early morning trade on Tuesday, shares are changing hands for $15.48 apiece, up 2.5%.
For some context, the ASX 200 is down 0.6% at this same time.
Telix shares have been on fire since plumbing a one-year closing low of $8.63 on 16 February. Indeed, with today's intraday lift factored in, the ASX 200 healthcare share has surged 79.4% since that low.
Here's what's catching investor interest today.
Image source: Getty Images
Telix shares jump on revenue growth
Telix shares are outperforming following the release of the company's second-quarter results (Q2 2026), covering the six months to 30 June.
Highlights included a 21% year-on-year revenue boost to US$247 million (AU$353 million). Second-quarter revenue was up 7% from the prior quarter.
The company's Precision Medicine segment brought in US$202 million of that quarterly revenue, a 30% increase from Q2 2025 and up 9% from last quarter.
The quarter also saw Telix finalise its strategic collaboration with antibody discovery and development platform developer Regeneron. The two companies will now work to jointly develop and commercialise next-generation radiopharmaceutical therapies.
Looking at what could impact Telix shares in the months ahead, the company forecasts that full-year 2026 revenue and other income will exceed US$1 billion. Revenue was reported to be tracking in line with the upper end of Telix's 2026 guidance of US$950 million to US$970 million, plus US$40 million non-refundable other income from Regeneron.
On the expenditure side, Telix increased its full-year 2026 R&D expenditure guidance to US$230 million to US$270 million. The company said the increased spend will support the advancement of high-value clinical programs beyond its original R&D forecast.
What did management say?
Commenting on the results helping boost Telix shares today, CEO Christian Behrenbruch said, "We delivered another quarter of growth with US dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio."
Behrenbruch added:
This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses.
Looking ahead, Behrenbruch concluded:
We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.
